MENU

Waltham cancer biotech goes public in $118M IPO

Xilio Therapeutics, the Waltham-based cancer biotech that rebranded from Akrevia Therapeutics back in early 2020, has made its Wall Street debut. The company raised $117.5 million in an IPO on Friday, selling nearly 7.4 million shares at $16 apiece.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story